Clinical Trial Update: The Benefit of Bermekimab in Patients With Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating bermekimab for systemic sclerosis (scleroderma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• bermekimab (bermekimab)

Snippet

Sponsor: Hellenic Institute for the Study of Sepsis | Conditions: Scleroderma, Systemic | Phase 2 | Status: COMPLETED